[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

NL8600899A - Werkwijze voor de bereiding van een oplossing van fenytoine of fenytoinenatrium, alsmede een aldus bereide oplossing. - Google Patents

Werkwijze voor de bereiding van een oplossing van fenytoine of fenytoinenatrium, alsmede een aldus bereide oplossing. Download PDF

Info

Publication number
NL8600899A
NL8600899A NL8600899A NL8600899A NL8600899A NL 8600899 A NL8600899 A NL 8600899A NL 8600899 A NL8600899 A NL 8600899A NL 8600899 A NL8600899 A NL 8600899A NL 8600899 A NL8600899 A NL 8600899A
Authority
NL
Netherlands
Prior art keywords
solution
phenytoin
sodium
choline
prepared
Prior art date
Application number
NL8600899A
Other languages
English (en)
Dutch (nl)
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Publication of NL8600899A publication Critical patent/NL8600899A/nl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/186—Quaternary ammonium compounds, e.g. benzalkonium chloride or cetrimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
NL8600899A 1985-05-20 1986-04-09 Werkwijze voor de bereiding van een oplossing van fenytoine of fenytoinenatrium, alsmede een aldus bereide oplossing. NL8600899A (nl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US06/735,932 US4642316A (en) 1985-05-20 1985-05-20 Parenteral phenytoin preparations
US73593285 1985-05-20

Publications (1)

Publication Number Publication Date
NL8600899A true NL8600899A (nl) 1986-12-16

Family

ID=24957819

Family Applications (1)

Application Number Title Priority Date Filing Date
NL8600899A NL8600899A (nl) 1985-05-20 1986-04-09 Werkwijze voor de bereiding van een oplossing van fenytoine of fenytoinenatrium, alsmede een aldus bereide oplossing.

Country Status (18)

Country Link
US (1) US4642316A (fr)
JP (1) JPS61268618A (fr)
AU (1) AU595790B2 (fr)
BE (1) BE904476A (fr)
CA (1) CA1268119A (fr)
CH (1) CH668594A5 (fr)
DE (1) DE3610330A1 (fr)
DK (1) DK100786A (fr)
ES (1) ES8707195A1 (fr)
FR (1) FR2581871B1 (fr)
GB (1) GB2175203B (fr)
IT (1) IT1190282B (fr)
LU (1) LU86383A1 (fr)
NL (1) NL8600899A (fr)
NZ (1) NZ215783A (fr)
PH (1) PH22922A (fr)
SE (1) SE8600998L (fr)
ZA (1) ZA862094B (fr)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3828156A1 (de) * 1988-08-19 1990-02-22 Astrapin Pharmazeutische Praep Stabile waessrige loesung von fluorouracil
WO1999004798A1 (fr) * 1997-07-22 1999-02-04 Warner-Lambert Company Fosphenytoine sodium lyophilise a usage parenteral
WO1999048876A1 (fr) 1998-03-20 1999-09-30 Warner-Lambert Company Monohydrate de phenytoine de sodium cristallin
US6274168B1 (en) 1999-02-23 2001-08-14 Mylan Pharmaceuticals Inc. Phenytoin sodium pharmaceutical compositions
AU2003288588A1 (en) * 2002-12-16 2004-07-09 Ranbaxy Laboratories Limited An extended release pharmaceutical composition of phenytoin sodium
NZ599464A (en) 2005-02-03 2014-03-28 Topotarget Uk Ltd Combination therapies using hdac inhibitors
DE102005019393A1 (de) * 2005-04-25 2006-10-26 Basell Polyolefine Gmbh Polyethylenformmassen für Spritzgussanwendungen
ES2380887T3 (es) 2005-05-13 2012-05-21 Topotarget Uk Limited Formulaciones farmacéuticas de inhibidores de la HDAC
AU2012213940B2 (en) * 2005-05-13 2015-03-26 Topotarget Uk Limited Pharmaceutical formulations of HDAC inhibitors
EP1957056A2 (fr) * 2005-11-10 2008-08-20 TopoTarget UK Limited Inhibiteurs d'histone desacetylase (hdac) pour le traitement du cancer
US8377979B2 (en) * 2005-12-05 2013-02-19 Taro Pharmaceuticals North America, Inc. Pharmaceutical formulation containing phenytoin sodium and magnesium stearate
CA2700173C (fr) * 2007-09-25 2016-10-11 Topotarget Uk Limited Procedes de synthese de certains composes d'acide hydroxamique
PL2262493T3 (pl) * 2008-03-07 2015-08-31 Onxeo Dk Branch Of Onxeo S A France Sposoby leczenia wykorzystujące wydłużony ciągły wlew belinostatu
GB0900555D0 (en) * 2009-01-14 2009-02-11 Topotarget As New methods
EP3777839A1 (fr) 2009-05-19 2021-02-17 Neuroderm Ltd Compositions pour administration continue d'inhibiteurs de la dopa décarboxylase
SI2640358T1 (en) 2010-11-15 2018-05-31 Neuroderm Ltd. Continuous administration of L-dopa, dopamine decarboxylase inhibitors, catechol-O-methyl transferase inhibitors, and compositions thereof
US9540330B2 (en) 2010-12-15 2017-01-10 Nektar Therapeutics Oligomer-containing hydantoin compounds
MX2014014902A (es) 2012-06-05 2015-03-04 Neuroderm Ltd Composiciones que comprenden apomorfina y acidos organicos y usos de las mismas.
CN106413754B (zh) 2014-03-13 2019-11-29 纽罗德姆有限公司 多巴脱羧酶抑制剂组合物
US10258585B2 (en) 2014-03-13 2019-04-16 Neuroderm, Ltd. DOPA decarboxylase inhibitor compositions
US11213502B1 (en) 2020-11-17 2022-01-04 Neuroderm, Ltd. Method for treatment of parkinson's disease
US11844754B2 (en) 2020-11-17 2023-12-19 Neuroderm, Ltd. Methods for treatment of Parkinson's disease
US11331293B1 (en) 2020-11-17 2022-05-17 Neuroderm, Ltd. Method for treatment of Parkinson's disease
WO2023205615A1 (fr) * 2022-04-18 2023-10-26 ISHA Therapeutics LLC Compositions de film antimicrobien à dissolution orale et leurs méthodes d'utilisation
US12109303B2 (en) 2022-04-18 2024-10-08 ISHA Therapeutics LLC Orally dissolving antimicrobial film compositions and methods of their use
US12161612B2 (en) 2023-04-14 2024-12-10 Neuroderm, Ltd. Methods and compositions for reducing symptoms of Parkinson's disease

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3749779A (en) * 1970-08-27 1973-07-31 American Home Prod Stable solutions of sodium diphenylhydantoin
JPS5221575B2 (fr) * 1972-03-18 1977-06-11
US4163058A (en) * 1977-04-22 1979-07-31 Interx Research Corporation Derivatives of 5,5-diphenylhydantoin exhibiting enhanced solubility and the therapeutic use thereof
US4260769A (en) * 1977-04-22 1981-04-07 Interx Research Corporation 5,5-Diphenylhydantoins

Also Published As

Publication number Publication date
DK100786D0 (da) 1986-03-05
FR2581871B1 (fr) 1990-05-11
DK100786A (da) 1986-11-21
SE8600998D0 (sv) 1986-03-05
SE8600998L (sv) 1986-11-21
ZA862094B (en) 1986-11-26
CA1268119A (fr) 1990-04-24
US4642316A (en) 1987-02-10
DE3610330A1 (de) 1986-11-20
NZ215783A (en) 1989-01-27
GB2175203B (en) 1988-09-14
GB8607383D0 (en) 1986-04-30
ES8707195A1 (es) 1987-07-16
AU5441286A (en) 1986-11-27
JPS61268618A (ja) 1986-11-28
BE904476A (fr) 1986-09-24
GB2175203A (en) 1986-11-26
IT1190282B (it) 1988-02-16
IT8647936A0 (it) 1986-04-24
LU86383A1 (fr) 1986-09-02
AU595790B2 (en) 1990-04-12
CH668594A5 (fr) 1989-01-13
ES555143A0 (es) 1987-07-16
PH22922A (en) 1989-01-24
FR2581871A1 (fr) 1986-11-21

Similar Documents

Publication Publication Date Title
NL8600899A (nl) Werkwijze voor de bereiding van een oplossing van fenytoine of fenytoinenatrium, alsmede een aldus bereide oplossing.
Egan et al. Quinoline anti-malarial drugs inhibit spontaneous formation of β-haematin (malaria pigment)
US4666927A (en) Pharmaceutical compositions of hydroxypyridones
US5626864A (en) Preparation of colloidal aqueous solutions of active substances of low solubility
US4912118A (en) Pharmaceutical compositions
KR20110114562A (ko) 보르테조밉 함유 약학적 조성물
Hampl et al. Metallomicelles made of Ni (II) complexes of lipophilic 2-pyridineketoximes as powerful catalysts of the cleavage of carboxylic acid esters
JP7464995B2 (ja) 液体薬学的製剤
EP0298192B1 (fr) Solutions stables et injectables de sels de vincristine
AU599034B2 (en) Furosemide salts
CA2810507A1 (fr) Derives d'homo et hetero-polyaminoacides de fullerene c60, procede de fabrication, et compositions pharmaceutiques les contenant
US4151188A (en) Arsenamide compound
NL8102362A (nl) Farmaceutische antitumor-preparaat; werkwijze voor de bereiding daarvan.
NL7906835A (nl) Etomidaat-bevattende infusievloeistof, alsmede werkwijze voor het intraveneus toedienen en bereiden daarvan.
AU2012212707B2 (en) Homo- and hetero-polyamino-acid derivatives of fullerene C60, method for producing same, and pharmaceutical compositions based on said derivatives
NL8502821A (nl) Metaalcomplexen van bis-indoolverbindingen en waterige farmaceutische preparaten met dergelijke verbindingen erin.
FI95139B (fi) Analogiamenetelmä terapeuttisesti käyttökelpoisen, kruunueetterillä substituoidun polysakkaridin valmistamiseksi
EP2035040A2 (fr) Préparation pharmaceutique injectable
RU2060031C1 (ru) Способ получения сарколизина для внутривенных инъекций
CA2486571C (fr) Composition medicinale
KR900001175B1 (ko) 프로카테롤 안정화 방법
JP2720079B2 (ja) 酸性非ステロイド性抗炎症薬含有薬剤
NL8303549A (nl) Injectieoplossing en werkwijze voor het bereiden daarvan.
CA1292944C (fr) Procede de preparation d'une solution pharmaceutique aqueuse d'un principe actif constitue d'un acide organique
Fawwaz et al. Anti-Tumor Activity of 1-ethyl-3-(3'-Dimethylaminopropyl) Carbodiimide. HCl Against Mouse Neuroblastoma C1300

Legal Events

Date Code Title Description
BV The patent application has lapsed